/Pinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degraders in Oncology
NEWS
Pinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degraders in Oncology
PRNewswire
2025/10/28Pinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degraders in Oncology
(PRNewsfoto/Pinetree Therapeutics) (PRNewsfoto/PineTree Therapeutics)
Summary
/PRNewswire/ -- Pinetree Therapeutics, a preclinical-stage biotechnology company pioneering targeted protein degraders for drug-resistant cancers, announced...